AIMS & OBJECTIVES
AIMS AND OBJECTIVES

1). To evaluate the efficacy of the clopidogrel (75 mg/day) versus aspirin (325 mg/day) in reducing risk of thrombotic events in stroke patients. Risk reduction is determined by a composite outcome group consisting of recurrent ischemic stroke, myocardial infarction or vascular death in an ischemic stroke patient.

2). To compare the safety profile and adverse outcomes of both the drugs in patients of acute ischemic stroke.